Additional file 2 of Integrative analysis of CRISPR screening data uncovers new opportunities for optimizing cancer immunotherapy

Additional file 2: Table S1. Summary of included screens. Table S2. The occurrence frequency of sensitizer and resistor genes in different cancer types. Table S3. Summary of 65 sensitizer genes and 40 resistor genes. Table S4. GO functional annotation of sensitizer and resistor genes. Table S5. The list of immune-related features. Table S6. Summary of studies associated with ICB treatment. Table S7. Summary of Tumor immunity-related OGs/TSGs. Table S8. Summary of ICB enhancer genes and ICB suppressor genes. Table S9. Summary of positive regulators and negative regulators. Table S10. Prediction of potential immunomodulatory agents.

附加文件2：表S1。纳入筛选研究概况。
表S2：不同癌症类型中增敏基因与耐药基因的出现频率。
表S3：65个增敏基因与40个耐药基因概况。
表S4：增敏基因与耐药基因的基因本体（Gene Ontology, GO）功能注释。
表S5：免疫相关特征列表。
表S6：与免疫检查点阻断（Immune Checkpoint Blockade, ICB）治疗相关的研究概况。
表S7：肿瘤免疫相关癌基因（oncogenes, OGs）与抑癌基因（tumor suppressor genes, TSGs）概况。
表S8：免疫检查点阻断增强基因与免疫检查点阻断抑制基因概况。
表S9：正调控因子与负调控因子概况。
表S10：潜在免疫调节药物预测。